CRC (colorectal cancer) is cancer of the colon or rectum that typically develops from abnormal mucosal growths and can spread if untreated.
Two studies link delayed colorectal cancer treatment to worse outcomes. A JAMA Oncology study of 112,672 patients found delays over six weeks hurt survival. High socioecological burden also delays care.
Kura Oncology's ziftomenib shows 96% complete response in frontline AML and $5.8M in early commercial sales; updated FIT-001 trial data for kidney cancer to be presented at 2026 summit; analysts see significant upside with an average target of $32.45.
Screening with colonoscopy or FIT in 278,280 Swedish 60-year-olds detected more stage I-II colorectal cancers than usual care, with advanced cases declining. Adverse gastrointestinal and cardiovascular events rose slightly in the first year.
Moleculin said its MIRACLE Phase 2B/3 AML trial is nearing first unblinding, with blinded CRc above 40% and CR around 30%. The first 45-subject readout is expected before June 30, 2026.
Recent advances in genetic science are shifting colorectal cancer screening toward direct detection of DNA changes. In India, CRC is now the fourth most common cancer, with more than 64,000 new cases and over 38,000 deaths reported in 2022.
Adagene and Incyte will collaborate on a Phase 1 study combining muzastotug with INCA33890 for MSS colorectal cancer patients, beginning in 2026. The collaboration marks the second instance where Adagene's SAFEbody technology is paired with a PD-1-based bispecific. Muzastotug has shown encouraging response rates in combination with pembrolizumab in previous trials.
The phase 3 ENVISION trial shows 80% complete response rate for novel bladder cancer chemoablative therapy. AI integration accelerates precision oncology through biomarker identification and targeted treatments. OncoPRO real-time symptom monitoring system enhances patient safety and clinical trial data capture.
Summit Therapeutics will participate in three investor conferences in March 2026, following FDA acceptance of its BLA for ivonescimab in lung cancer with a PDUFA date of November 14, 2026.
New combination therapies demonstrate improved outcomes in advanced anal and colorectal cancers, with retifanlimab plus chemotherapy approved for anal cancer and onvansertib showing strong efficacy signals in RAS-mutated colorectal cancer.
Researchers at Stony Brook University developed an oral vaccine using modified Listeria monocytogenes that generates anti-tumor immune responses in the gut and significantly improves colorectal cancer control when combined with checkpoint inhibitors.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07689812 |
A Multicenter Randomized Open-Label Trial Evaluating ctDNA-Guided Interruption Versus Standard of Care Immune-Checkpoint Inhibitor (ICI) Therapy In Patients With Advanced / Metastatic Solid Tumors. |
NOT_YET_RECRUITING | NA |
| NCT07649057 |
A Study of a Urine Test to Detect Colorectal Cancer |
RECRUITING | |
| NCT07620743 |
Noninvasive Early Diagnosis of Colorectal Cancer Using Odor-Targeted Capture, Point-of-Care Testing, and Intelligent Analysis |
NOT_YET_RECRUITING | |
| NCT07511972 |
Study of NGM707 in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies |
WITHDRAWN | PHASE2 |
| NCT07397338 |
Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors |
RECRUITING | PHASE1/PHASE2 |
| NCT07381309 |
Oncolytic Virus (H101) + SBRT + Chemotherapy + Targeted Therapy + Immunotherapy for Unresectable CRLM |
NOT_YET_RECRUITING | PHASE2 |
| NCT07349537 |
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors |
RECRUITING | PHASE1 |
| NCT07321106 |
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of CBI-1214 T Cell Engager in Participants With Advanced or Metastatic MSS/MSI-L Colorectal Cancer |
RECRUITING | PHASE1 |
| NCT07283367 |
A Phase Ib/II Trial of HS-20110 Combination Therapies in Advanced Colorectal Cancer Patients. |
RECRUITING | PHASE1/PHASE2 |
| NCT07204574 |
The Phase 1b/IIa, Open-label, Dose Escalation and Dose Expansion to Evaluate Safety, Tolerability, and Preliminary Efficacy of the Combination of HCB101, Cetuximab/Bevacizumab, and FOLFOX/FOLFIRI in Advanced or Metastatic Colorectal Cancer |
RECRUITING | PHASE1/PHASE2 |
